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ABSTRACT 
Recent studies suggest that the evolutionary history of a cancer is important in forecasting clinical 
outlook. To gain insight into the clonal dynamics of multiple myeloma (MM) and its possible 
influence on patient outcome we analysed whole exome sequencing tumor data for 333 patients 
from Myeloma XI, a UK phase III trial and 434 patients from the CoMMpass study, all of which had 
received immunomodulatory therapy (IMiD). By analysing mutant allele frequency distributions in 
tumors we found that 17-20% of MM is under neutral evolutionary dynamics. These tumors are 
associated with poorer patient survival in non-intensively treated patients, consistent with 
reduced therapeutic efficacy of micro-environment modulating IMiD drugs. Our findings provide 
evidence that knowledge of the evolutionary history of MM has relevance for predicting patient 
outcome and personalising therapy.  
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INTRODUCTION 
 
Advances in the treatment of multiple myeloma (MM) in form of proteasome inhibitors and 
immunomodulatory drugs (IMiDs) have significantly improved patients’ outcome, however MM 
remains a remitting-relapsing disease in most patients.
1
 
Although rearrangements at the immunoglobulin (IGH) loci and hyperdiploidy (HRD) are key 
initiating events in MM oncogenesis, it is likely by inference from the study of other cancers, that 
the evolutionary history of MM is important in determining patient outcome.
2,3
 This is because 
prognosis in cancer is strongly associated with the development of resistant sub-clones.
4
 Recent 
studies of solid cancers have challenged the classical Darwinian model of cancer evolution based 
on a changing sub-clonal dominance.
5-7
 Observations have suggested that after malignant 
transformation, sub-clones that have distinct mutational profiles that can coexist for long periods 
of time.
8,9
 Such a model of neutral tumor evolution is consistent with only a handful of recurrent 
driver alterations identified to date, indicating that they all occurred in the primordial cancer cell 
and that subsequent clonal outgrowths are relatively rare.  
The mutant allele frequency distribution has been shown to predict the expected pattern of sub-
clonal mutations within a tumor under neutral evolutionary dynamics from a single baseline 
sample.
10
 To gain insight into the clonal evolution of MM and its impact on phenotype we 
analysed whole exome sequencing (WES) tumor data from two independent series of MM 
patients.
11,12
 We report that a high proportion of MM tumors are under neutral evolutionary 
dynamics and that these tumors are associated with a worse survival in patients receiving 
iMiDtherapy.  
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METHODS 
 
We analysed WES tumor data from: (i) 333 patients from Myeloma XI (NCT01554852, 
CRUK/09/014) an open-label randomised controlled randomised phase III trial comparing 
thalidomide against lenalidomide at induction and lenalidomide maintenance against no 
maintenance in both transplant eligible and non-eligible patients (Supplementary Methods, 
Supplementary Fig. 1) 
11,12
. Copy number changes in tumors were based on MLPA data and qRT-
PCR used to assign translocation status.
13,14
 (ii) 434 patients from the Multiple Myeloma Research 
Foundation’s CoMMpass study, which had received IMiD therapy (NCT01454297; dbGaP accession 
phs000748.v5.p4; IA9 data tranche; Supplementary Methods). Translocations status and copy 
number abnormalities from CoMMpass data were called from whole genome sequencing, exome 
and RNA sequencing (FISH-seq). Hyperdiploid cases with no detected translocation by FISH-seq, 
but classified by conventional FISH were considered as missing. 
 
Modelling tumor evolution  
The distribution of mutant allele frequencies in each MM tumor was used to detect neutral 
evolution as previously described
10
 (Supplementary Methods). Briefly, mutations were only 
included if the read depth was ≥ 10 and the number of mutant alleles was ≥3 and at least 12 
mutations matching these criteria had to be present in a sample to be included.
10
 Preliminary 
analysis showed that mosaic copy number changes, e.g. Hyperdiploidy could give rise to a false 
sub-clone status and all cases were corrected for copy number.
13-15
 By excluding public mutations 
present at mutational frequencies ≥0.3, the influence of undetermined normal CD138 cell 
contamination was controlled. Mutations at a frequencies ≤ 0.12 were also excluded, since they 
reach the limit of reliable detectability in bulk sequencing data.
10
  For each tumor sample the 
cumulative number of mutations, M(f), was tested for linearity with the inverse of the frequency 
(1/f) as predicted by M(f)=µ/β( 1/f - 1/f
max
) for neutral tumor evolution. A tumor sample was 
considered to have evolved neutrally if R
2
 ≥0.98, as previously advocated.
10
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RESULTS AND DISCUSSION 
 
Evidence of neutral evolution was shown in 20% of tumors (65/333) from the Myeloma XI trial 
(Fig.1; Supplementary Fig.2 and 3). Evidence for neutral evolution was not influenced by 
sequencing depth, exome coverage or number of mutations (Supplementary Table 1). There was 
no significant association between neutral clonal evolution in tumors by age at diagnosis, sex or 
International Staging System (ISS) stage. In the CoMMpass study 17% of tumors (74/434) from 
patients treated with IMiDs showed evidence of neutral evolution.  
 
In both the Myeloma XI and CoMMpass series tumors with IGH translocations were more likely to 
show evidence of neutral evolution than hyperdiploidic tumors;  Respective median R
2
 values for 
Myeloma XI and CoMMpass tumors being 0.963 vs. 0.956 (P=0.002), and  0.957 vs. 0.947 (P=0.034) 
(Fig. 2 , Supplementary Fig. 4 and 5). 
 
In both series of patients that received non-intensive therapy, (i.e. no high-dose alkylating 
consolidation), neutral tumour evolution was associated with worse progression free survival (PFS) 
and overall survival (OS); In the Myeloma XI trial, median PFS was 15.6 as compared with 20.5 
months (Logrank P=0.019) and median OS was 27.3 compared with 49.6 months (P<0.001) for 
neutral and non-neutral tumors, respectively. In the CoMMpass study, median PFS was 18.7 as 
compared with 28.1 months (P=0.036) and median OS was 21.3 and not reached (P=0.029), 
respectively. In contrast no difference was shown for patients in receipt of intensive alkylating 
therapy based on high-dose melphalan and autologous transplantation.  
 
To address the possibility of potential co-linearity between tumor evolution status and established 
genetic risk factors in non-intensively treated patients that may have confounded outcome we 
performed a multi-variable survival analysis (Supplementary Table 2). Neutral evolution was 
shown to be prognostically independent of ISS, adverse IGH translocations, gain(1q) and TP53 
deletion.  
 
The observation that tumors with IGH translocations have a higher degree of evolutionary 
neutrality than hyperdiploid tumors may reflect the fact that early mutational events brought 
about by IGH translocations provide increased tumor fitness as compared to hyperdiploidy. 
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Importantly, IGH translocations are present in all sub-clones, thus potentially mediating relative 
tumor independence from external factors such as microenvironment growth factors that might in 
a weaker oncogenic context contribute to sub-clonal selection.
16
  
 
Tumor microenvironment factors are well established to influence MM cell survival and 
proliferation.
17
 Therapy with IMiDs modulates the tumor microenvironment, but in the context of 
neutral evolution and presence of early clonal strong oncogenic driver events this mechanism of 
therapy may be less efficacious. This contrasts with intensive alkylator therapy, which targets the 
tumor cell directly and non-specifically through DNA adduct formation. This ‘de-bulking’ effect 
may reset the sub-clonal structure, potentially reducing the impact of a neutral or non-neutral 
evolutional tumor history (Supplementary Fig. 6), which may explain the similar survival in both 
groups of intensively treated patients.  
 
In summary, we demonstrate that a significant proportion of MM is under neutral evolutionary 
selection. Importantly, such tumors tend to confer a poorer patient survival in the context of 
microenvironment modulating therapies. Our findings therefore provide further evidence that 
knowledge about the evolutionary dynamics of MM has potential to inform treatment decisions. 
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FIGURE LEGENDS 
Figure 1: Influence of neutral evolutionary dynamics on overall survival and progression-free 
survival in Myeloma XI and CoMMpass studies. Kaplan-Meier curves comparing neutral cases (R2 
≥ 0.98) versus non-neutral cases (A) progression-free survival (PFS) of Myeloma XI cases in the 
non-intensive treatment arm; (B) overall survival (OS) of Myeloma XI cases in the non-intensive 
treatment arm; (C) PFS of Myeloma XI cases in the intensive treatment arm; (D) OS of Myeloma XI 
cases in the intensive treatment arm; (E) PFS of non-autologous transplant CoMMpass cases 
receiving an IMID; (F) OS of non-autologous transplant CoMMpass cases receiving an IMID; (G) PFS 
of autologous transplant CoMMpass cases receiving an IMID; (H) OS of autologous transplant 
CoMMpass cases receiving an IMID. The red line depicts the survival curve for tumors with neutral 
evolutionary dynamics and the black line depicts the survival curve for tumors with non-neutral 
evolutionary dynamics. Horizontal ticks on the survival curves show censored cases. 
 
Figure 2: Association of neutral evolutionary dynamic with IgH translocations in Myeloma XI and 
CoMMpass studies. Violin-plot of the neutral evolutionary dynamics measured by R2 by (a) 
Myeloma XI (b) CoMMpass. The distribution shows kernel density estimation where a broader 
shape represents a higher probability of a value. Thick black bar represents the interquartile range. 
Thin line represents the 95% confidence interval. The dotted line corresponds to the R2=0.98 
threshold for discriminating neutral from non-neutral tumors. Statistical differences between 
experimental groups were evaluated by Wilcoxon rank sum test. P < 0.05 was considered 
statistically significant. 


